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Progressive loss of muscle mass and strength is a physiological consequence of aging, and without interventions, it
usually deteriorates into sarcopenia. In this study, the hypothesis that combined special nutritional–physiother-
apeutical intervention to prevent or reverse this biological deterioration in elderly people was tested. The effects of
the regular resistance muscle training (PT, n= 17) alone and the combined exercise+ special nutrition therapy
containing whey protein and vitamin D (PT+NT, n= 17) were monitored for 3 months in 34 elderly patients
(12 men and 22 women; mean age: 66.47 years) randomly distributed into two groups at a long-term care facility.
Physical exercise alone did not result in signiﬁcant improvement in skeletal muscle mass or strength, whereas
combined intervention signiﬁcantly increased the muscle strength (22.51 ± 2.35 vs. 24.54 ± 2.65, x¯ ± SEM, kg,
p= 0.027). When therapeutic responses to the intervention were compared, a signiﬁcant advantage of PT+NT over
PT was found. The same trend was found when the non-signiﬁcant post-therapeutic alterations (χ2 test) of the
distribution of normal vs. pre-sarcopenic+ sarcopenic conditions within the two groups were compared. Combined
intervention (PT+NT) is necessary for the efﬁcient protection of the musculature in the high-risk elderly patients.
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Introduction
Progressive loss of muscle mass and strength is a physiological process during advanced
aging (14). Sarcopenia, which is the critical combined loss of the skeletal muscle mass,
strength, and functional capacity, is a pathologic phase of this biological deterioration (14).
Frailty, immobility, loss of self-maintenance, malnutrition, cachexia, and death are all
consequences of severe progressive sarcopenia. A gradual decrease in muscle mass (19,
20, 23) may be observed already from the age of 40–50 years, and the prevalence of
sarcopenia signiﬁcantly increases with advanced age (5, 21, 30). In institutionalized elderly
people, increasing deterioration of musculature leading to progressive sarcopenia is leading
risk (3, 21, 22). The prevalence of the different stages of the loss of muscle mass and strength
Corresponding author: Dr. Szabolcs Várbíro´ MD, PhD
2nd Department of Gynecology and Obstetrics, Semmelweis University
78/a Üllői road, H-1082 Budapest, Hungary
Phone: +36 20 335 9099; Fax: +36 1 333 4934; E-mail: varbiroszabolcs@gmail.com
2498-602X/$ 20.00 © 2016 Akadémiai Kiado´, Budapest
ranges from 10% to 60% in the elderly people (5, 21, 30). The geriatric syndrome
sarcopenia – which is a critical stage of this neuromuscular problem – is of complex
etiology and its clinical appearance has complex consequences and pathological components
superposed to the physiological muscle aging. Increased physical activity may slow but not
halt this chronic process in the aged high-risk elderly group (25, 32). Proposed pillars of
relatively successful therapeutic strategies are regular muscle training and speciﬁc nutritional
therapy (increased intake of protein and complimentary nutrients) (7, 15, 27–29). Whey
protein, a fast-acting protein that is quickly digested and becomes fast-absorbing peptides and
amino acids, can potentially be the most effective in maintaining adequate anabolic/catabolic
balance in the musculature of elderly individuals. Daily protein (1.2–1.5 g/kg/bodyweight)
and bolus protein intakes (at least 25–30 g of high-quality protein per meal) could sufﬁciently
stimulate muscle protein synthesis in both the healthy and sarcopenic elderly people (2, 9, 13,
24). It is now clear that the anabolic efﬁcacy of the various amino acids is different, and a
complex mixture of essential amino acids with an added extra quantity of leucine (8) is the
most efﬁcient. Increased vitamin D intake is also an essential therapeutic component in the
prevention of not only osteoporosis but also sarcopenia (7, 15, 28, 29). In spite of these
promising ﬁndings, it is known that the sensitivity of the muscle protein synthesis in the
elderly people is very low to anabolic stimuli (10). Our hypothesis was that in the case of
high-risk elderly patients in institutions, only the combination of physical exercise and
scientiﬁcally planned optimal nutritional intervention (FortiFit, Nutricia providing all the
above-mentioned components) may halt or slow the progress of the critical deterioration of
the musculature. This hypothesis was tested at a large long-term care facility.
Materials and Methods
The study was approved by the local institutional Committee of Science and Research Ethics
and was performed in accordance with the Helsinki declaration. All patients agreed to
participate and provided informed consent.
Elderly people with comorbidities or comorbid conditions in nursing or care homes are
at very high risk of critical muscle mass and strength loss, sarcopenia, falls, suboptimal
response to therapy, and frailty syndrome. The primary objective of this study was to
compare the effect of combined nutrition and exercise therapy to exercise therapy alone on
the reduction of progressive loss of muscle mass and strength in the elderly people with
comorbid conditions (15). The secondary objective was to compare the prevalence of normal
or sarcopenic muscle status in elderly patients receiving exercise or exercise + nutritional
intervention.
A total of 34 elderly patients, as voluntary subjects, were randomly selected and
distributed into two groups (patients were randomized on initial muscle mass and strength
because the study focused to avoid initial inter-group differences of muscle mass and
strength) with 17+ 17 members for a 3-month therapeutic intervention program at a large
long-term care facility in Budapest. The basic primary selection criteria were as follows: the
subjects complained of muscle strength loss but had the ability to adhere to the study
protocol, i.e., suitable mobility and mental state. About 30 participants had normal cognitive
function, and two participants in the PT group and also two participants in the PT +NT group
had mild cognitive disturbance (>15, deﬁned by a Mini-Mental State Examination). Patients
were excluded from the study if it was anticipated that the physical and the medical nutrition
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therapies could not be carried out due to previous underlying causes, such as malignant
disease 5 years preceding the study, kidney failure, signiﬁcant liver disease, poor cardiac
status (pacemakers), or such physical–mental handicaps that made it impossible for the
patient to fully participate in the physiotherapy regime.
Diagnostic procedures were as follows: ﬁrst, evaluation of patients based on the
inclusion and exclusion criteria then, the measurement of the skeletal muscle mass (kg)
and the fat-free mass (kg) carried out by bioelectrical impedance analysis (InBody
370 device); the derivation of fat-free mass index (FFMI, kg/m2) and muscle strength
(handgrip) was done by electronic hand dynamometer (Carmy EH101 device), and muscle
function (the short physical performance, SPPB) was measured according to the latest
methodological techniques discussed in the consensus papers (6, 14). Body composition was
measured by InBody analyzer, with each patient having fasted, urinated, and undressed
except for underwear. All jewelry and wristwatches were removed before the measurement.
The diagnosis of pre-sarcopenia and sarcopenia was established on the basis of the summed
muscle mass (fat-free mass), muscle strength (handgrip), and muscle performance (SPPB)
results (6, 14). The cut-off points of sarcopenia are based on the FFMI (data from
bioimpedance analysis: men FFMI< 17 kg/m2; women FFMI< 15 kg/m2), the handgrip
measurement adjusted for body mass index (BMI, kg/m2) and gender (men: BMI≤ 24≤
29 kg, BMI 24.1–26≤ 30 kg, BMI 26.1–28≤ 30 kg, BMI> 28≤ 32 kg; women: BMI≤
23≤ 17 kg, BMI 23.1–26≤ 17.3 kg, BMI 26.1–29≤ 18 kg, BMI> 29≤ 21 kg), and
the SPPB< 8 (SPPB: standing balance, gait speed, and chair sit-to-stand) (6, 12, 14).
All the above-mentioned parameters were measured both at the start and at the end of
the study.
All the patients in both the groups with 17+ 17 members participated in the same
physiotherapeutic program. The program provided regular, standard length physiotherapy
sessions. The physiotherapy session, which was led by a certiﬁed physiotherapist, mostly
consisted of strengthening exercise and included complex exercises. This regime was
standardized for both groups (30 min twice a week). The regime included a 5-min
warm-up, resistance band muscle strengthening exercises for both the upper and the lower
limbs, core strengthening exercises performed in a sitting position, followed by muscle
strengthening and stretching exercises. The ﬁrst group (5 men and 12 women) received only
this standard physiotherapy (PT group) for 3 months. However, the second group (7 men and
10 women) was provided with an additional special muscle protecting nutritional therapy
(NT) for the same period (PT+NT group). It is important to note that in this study, it was not
possible to establish a “real” control group with no physiotherapy at all, as allowing
progressive muscle mass loss and the consequent frailty of highly vulnerable elderly patients
would have been unethical.
The medical nutrition intervention was based on a recently developed consensus
regarding the potentially efﬁcient muscle protecting nutritional components in the elderly
people (7, 8, 15, 28, 29). Patients were randomized to receive either the intervention of
physiotherapy (PT) or the physiotherapy combined with the nutrition therapy (PT+NT) (NT
with FortiFit, oral nutritional supplement, and food for special medical purposes). The
product contained 20 g whey protein, 10 g essential amino acid mixture, 3 g total leucine, 9 g
carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and ﬁbers per
serving. It was provided as a 40 g powder to be reconstituted with 125 ml of water and was
offered twice daily, before breakfast and before lunch, to provide an adequate bolus of protein
in addition to the meals (2).
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Statistical analysis
Comparisons between the two groups were made by two-sample t-tests, and changes within a
group (comparisons between parameters at the beginning and at the end of the study) were
tracked with one-sample t-tests. In both cases, p< 0.05 was considered signiﬁcant. The
results are shown as the mean ± SEM. The statistical comparisons on the distribution of
normal or pre-sarcopenic/sarcopenic conditions in the two groups were carried out by χ2 test
(distribution before vs. after the 3-month interventions in the PT and PT+NT groups/intra-
group comparisons, then the intra-group changes were compared with each other, as inter-
group comparisons). Excel and GraphPad Prism software were used for the statistical
analysis.
Results
Baseline physiological parameters
The patients were randomized by initial muscle mass and strength; at the beginning of the
study, no signiﬁcant difference was found between the two groups regarding age [PT group
66.35 ± 1.79 vs. PT+NT group 66.59 ± 1.63 years, n.s.], muscle mass (PT group 24.03 ±
1.38 kg vs. PT+NT group 21.86 ± 1.22 kg, n.s.), muscle strength (PT group 23.73 ± 2.06 kg
vs. PT+NT group 22.51 ± 2.35 kg, n.s.), muscle performance value (SPPB scores: PT group
9.11 ± 2.87 vs. PT+NT group 6.88 ± 3.65, n.s.), and height (PT group 159.5 ± 2.9 cm vs.
PT+NT group 162.8 ± 2.4 cm, n.s.). The initial values of body weight in PT group were
71.47 ± 3.26 kg vs. in PT+NT group were 59.87 ± 3.35 kg (p< 0.05). It should be noted that
the randomization was focused on the muscle mass and strength. However, as the slight inter-
group difference remained also after the interventions and the intra-group changes did not
show any inter-group differences (ΔPT 0.388 ± 1.162 kg vs. ΔPT+NT 1 ± 0.643 kg, n.s.), it
did not inﬂuence the therapeutic responses of indexed values of muscle mass and strength
parameters for evaluating the stages or absence of sarcopenia.
Responses of skeletal mass and strength to interventions
Muscle strength and muscle mass values following the 3-month PT and PT +NT inter-
ventions: contrary to the tendency of progression usually encountered in sarcopenia, no
signiﬁcant changes were found (Fig. 1) either in skeletal muscle mass or in muscle strength
in the PT group in comparison to the baseline values measured at the beginning of the study
(skeletal muscle mass before vs. after: 24.03 ± 1.38 kg vs. 22.98 ± 1.41 kg, x¯ ± SEM, n.s.;
muscle strength before vs. after: 23.73 ± 2.056 kg vs. 22.18 ± 2.19 kg, x¯ ± SEM, n.s.). In the
PT +NT group, the skeletal muscle mass (skeletal muscle mass before vs. after: 21.86 ±
1.21 kg vs. 22.26 ± 1.22 kg, x¯ ± SEM, n.s.) did not show signiﬁcant difference, but
individual muscle strength scores increased signiﬁcantly compared with the control values
measured at the beginning of the study (muscle strength before vs. after: 22.51 ± 2.35 kg vs.
24.54 ± 2.65 kg, x¯ ± SEM, signiﬁcant difference, p= 0.027). The results are shown in
Fig. 1.
Inter-group comparison of the responses to PT and PT+ NT interventions
Comparing the intra-group changes of muscle strength and muscle mass in the PT and PT+
NT groups following the 3-month interventions, it was found that the combined PT+NT
intervention induced changes represented a positive and statistically signiﬁcant shift in the
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direction of skeletal muscle mass and strength increase when they were compared with the
alterations induced by the single PT intervention (see Fig. 2).
Analysis (χ2 test) on potential changes of the distribution of normal and pre-sarcopenic+
sarcopenic cases in the two groups after the therapeutic interventions: as a ﬁnal step, the
post-interventional intra-group changes of the distribution of normal vs. pre-sarcopenic+
sarcopenic conditions induced by PT or PT+NT were analyzed by the χ2 test. Then, the
inter-group differences of therapeutic responses of PT group vs. PT+NT group were
analyzed using the same test. The results are presented in Table I. The statistical analysis
of the distribution of normal and pathologic conditions indicated no signiﬁcant changes after
the two different types of therapeutic interventions in either the PT or the PT+NT group.
However, when these slight non-signiﬁcant therapeutical distribution alterations of the two
groups were compared by the χ2 test (inter-group comparison of the intra-group alterations), a
statistically signiﬁcant (p< 0.01) shift from pathological to normal condition of the muscu-
lature of the members of the PT+NT group was found when it was compared with the
PT group.
Fig. 1. Muscle strength (kg) and muscle mass (kg) values before and after the 3-month program in the group
receiving regular and standardized physiotherapy (muscular exercise) (PT; see A) and the group receiving
physiotherapy + special medical nutrition therapy (FortiFit) (PT+NT; see B) are shown as mean ± SEM. Signiﬁcant
difference: *p= 0.027
Fig. 2. Comparison of the changes
induced by physiotherapy alone
(group PT) and by the combined
physiotherapy+medical nutrition
therapy (group PT+NT) in
muscle strength (x¯ ± SEM, kg) and
muscle mass (x¯ ± SEM, kg).
Signiﬁcant differences:
*p= 0.013 and ** p= 0.038
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Discussion
The decrease of muscle mass and muscle strength seen in the aging population is an
unavoidable part of physiological aging (19, 23). The progress of this process is vastly
exacerbated by pathological risk factors, e.g., in the case of elderly residents with multiple
chronic comorbidities in care or in nursing homes with higher prevalence of severe
sarcopenia (3, 21, 22), which has been recently deﬁned by combined diagnostic criteria
(14). The progression of sarcopenia leads to further complications, such as loss of indepen-
dence and life-threatening gait instability, falls, frailty syndrome, and ﬁnally death (1, 18, 21).
Having regard to all these physiological–pathophysiological challenges, it is an important
result of this study, that the combined physiotherapy + special nutritional therapy containing
whey protein rich in essential amino acids – leucine – and vitamin D (PT+NT) resulted in a
signiﬁcant improvement of muscle strength in institutional care at high risk of pathological
neuromuscular deterioration (14) and known for not always giving satisfactory therapeutic
responses to muscle protective interventions (15). Beyond that, the importance of the special
nutritional therapy (NT) in this therapeutic combination was shown by ﬁnding a positive shift
in the changes of both the muscle mass and strength induced by the PT+NT intervention
when it was compared with those induced by PT intervention alone. Although numerous
encouraging ﬁndings have been available on the positive effects of enhanced physical activity
(27), and adequate qualitative and increased quantitative uptake of proteins (7, 15, 28, 29),
these procedures even in their combinations were often unsuccessful in the elderly people
(7, 10, 11) due to the low sensitivity to any anabolic stimulation of muscle protein synthesis
(10) and the substantial and age dependently increasing biological differences (10) in the
elderly population. The EWGSOP study’s consensus deﬁnition of sarcopenia has more
clearly deﬁned, where the border lies between the physiological loss of muscle mass,
strength, or performance and the pathological stage sarcopenia (14). There is a very high
risk of progressive sarcopenia in the elderly population with comorbidities who are residing
in long-term care facilities (3, 21, 22) and in these advanced pathological stages of the
muscular deterioration, weaker therapeutic responses must be expected. As this study
included both patients with physiological loss of muscle mass, strength, and performances
Table I. The distribution of the normal vs. pre-sarcopenic+ sarcopenic conditions in the two groups before and after
the PT and PT+NT interventions (intra-group differences) and the comparison of the therapeutic responses of the
two groups (inter-group differences) by χ2 test
Condition distribution (NS vs. PS+ S)
Intervention
(groups) Before After
Change (χ2)
(intra-group
differences)
Comparison of
changes (inter-group
differences)
PT NS 11 9 n.s. Signiﬁcant difference
p< 0.001 (χ2)
PS+ S 6 (2+ 4) 8 (4+ 4)
PT+NT NS 3 7 n.s.
PS+ S 14 (3+ 11) 10 (3+ 7)
NS, no sarcopenia; PS, pre-sarcopenia; S, sarcopenia; χ2: chi-square test
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and ones with sarcopenia+ pre-sarcopenia, it was also possible to test the capability of the
single and combined therapeutic interventions for preventing or reversing sarcopenia.
The χ2 test was an appropriate statistical method to compare the potential intra-group
changes and inter-group differences regarding the prevalence of normal and pathological
(pre-sarcopenic+ sarcopenic) status. An important ﬁnding on the advantage of the com-
bined PT+NT intervention compared with the changes induced by the physiotherapy (PT)
intervention alone was that physiotherapy combined with FortiFit, whey protein–amino
acid–leucine–vitamin nutritional mixture (PT+NT), had resulted in a shift to normal stages
in the distribution of the normal vs. pre-sarcopenic+ sarcopenic conditions. This shift
could be interpreted as a signiﬁcant relative advantage of PT+NT intervention either in
preventing or reversing the stage of (pre)sarcopenia in addition to the muscle mass
and strength results. To evaluate the signiﬁcance of the latter ﬁndings, it must be
emphasized that without therapeutic interventions, slow, but continuous and progressive
deterioration of the musculature could be expected in the highly vulnerable elderly patients
of the study.
Having considered all the ﬁndings of the study, it must be conceded that even the
beneﬁcial alterations induced by PT+NT combined intervention were rather modest, partial,
or only relative advantages compared with the changes that resulted from the effect of PT
intervention alone. This can be interpreted by such limitations of the study as low case
numbers and the medium frequency of standardized physical training (twice a week).
Another limitation of the study was the use of the BIA method (instead of DEXA), but
using InBody analyzer was easy, non-invasive, relatively inexpensive, and could be
performed on any elderly person because it was portable and there was no ionizing radiation
during the measurement (31). The other explanation for missing more characteristic beneﬁ-
cial muscle protective effects even of the combined PT+NT therapy is the lack of a real
control group. Creating a real control group with no physical activity in a long-term care
facility (with presumably a natural steady decline of muscle mass and strength of the elderly
subjects with comorbidities over 3 months) was not considered for ethical reasons. Thus, the
evaluation of our therapeutic results was less sensitive in this highly vulnerable age
group. But it could be argued that even the lack of post-interventional change of muscle
parameters could be hypothetically interpreted as successful prevention of an expectable mild
decline.
This study could demonstrate the effectiveness of the combined physiotherapy+ special
nutritive therapy (26). Both components of this combination seem important for the efﬁcacy.
Although the single PT intervention did not result in signiﬁcant post-interventional changes
in the observed muscular parameters, several studies refer to its signiﬁcance in the efﬁcacy of
any PT+NT combination. For example, regular enhanced physical activity of elderly
master-athletes (25) signiﬁcantly reduced although could not fundamentally prevent, the
loss of muscle mass and strength over time when they were compared with the control
population. In turn, immobilization induces the resistance of muscles to anabolic stimulation
(17), and the combinations of these two factors are the major contributors to the development
and progression of sarcopenia (16).
Beyond this study, the muscle protective importance of the special NT intervention was
also demonstrated by another examination: a 13-week intervention of a vitamin D and
leucine-enriched whey protein oral nutritional supplement resulted in improvements in
muscle mass and lower extremity function among sarcopenic elderly adults with limited
mobility (4).
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Conclusions
Special nutrition intervention (fast protein, essential amino acids, leucine-enriched mixture
with vitamin D) is necessary to accomplish muscle protective efﬁcacy of regular physical
exercise even in those elderly people who are at the highest risk of sarcopenia.
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